• IGM Biosciences Inc IGMS.OQ reported a quarterly adjusted loss of 51 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -83 cents. The mean expectation of four analysts for the quarter was for a loss of 41 cents per share. Wall Street expected results to range from -55 cents to -21 cents per share.

• Revenue rose 0.4% to $499.00 thousand from a year ago; analysts expected $3.10 million.

• IGM Biosciences Inc's reported EPS for the quarter was a loss of 86 cents​.

• The company reported a quarterly loss of $52.89 million.

• IGM Biosciences Inc shares had held steady so far this quarter and lost 81.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 25.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for IGM Biosciences Inc is $2.00

This summary was machine generated from LSEG data May 14 at 06:26 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)